193 related articles for article (PubMed ID: 23737518)
1. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
Zhang X; Hernandez I; Rei D; Mair W; Laha JK; Cornwell ME; Cuny GD; Tsai LH; Steen JA; Kosik KS
J Biol Chem; 2013 Jul; 288(30):22042-56. PubMed ID: 23737518
[TBL] [Abstract][Full Text] [Related]
2. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
[TBL] [Abstract][Full Text] [Related]
3. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice.
Peng Y; Hu Y; Xu S; Li P; Li J; Lu L; Yang H; Feng N; Wang L; Wang X
J Alzheimers Dis; 2012; 29(2):379-91. PubMed ID: 22233765
[TBL] [Abstract][Full Text] [Related]
4. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
[TBL] [Abstract][Full Text] [Related]
5. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
6. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment.
Watamura N; Toba J; Yoshii A; Nikkuni M; Ohshima T
J Neurosci Res; 2016 Jan; 94(1):15-26. PubMed ID: 26400044
[TBL] [Abstract][Full Text] [Related]
7. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.
Park H; Kam TI; Kim Y; Choi H; Gwon Y; Kim C; Koh JY; Jung YK
Hum Mol Genet; 2012 Jun; 21(12):2725-37. PubMed ID: 22419736
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
10. Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.
Wisely EV; Xiang YK; Oddo S
Hum Mol Genet; 2014 Aug; 23(15):4024-34. PubMed ID: 24626633
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A.
Martin L; Magnaudeix A; Esclaire F; Yardin C; Terro F
Brain Res; 2009 Feb; 1252():66-75. PubMed ID: 19071093
[TBL] [Abstract][Full Text] [Related]
12. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.
Hu JP; Xie JW; Wang CY; Wang T; Wang X; Wang SL; Teng WP; Wang ZY
Brain Res Bull; 2011 May; 85(3-4):194-200. PubMed ID: 21435383
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice.
Hu Y; Lai J; Wan B; Liu X; Zhang Y; Zhang J; Sun D; Ruan G; Liu E; Liu GP; Chen C; Wang DW
Neurotoxicology; 2016 Mar; 53():290-300. PubMed ID: 26945731
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
[TBL] [Abstract][Full Text] [Related]
15. Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice.
Joshi YB; Chu J; Praticò D
Aging Cell; 2013 Aug; 12(4):706-11. PubMed ID: 23634895
[TBL] [Abstract][Full Text] [Related]
16. Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and τ pathologies in a mouse model of Alzheimer's disease.
Peng Y; Hu Y; Xu S; Rong X; Li J; Li P; Wang L; Yang J; Wang X
J Pharmacol Exp Ther; 2014 Aug; 350(2):361-74. PubMed ID: 24893984
[TBL] [Abstract][Full Text] [Related]
17. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation.
Bao XQ; Li N; Wang T; Kong XC; Tai WJ; Sun H; Zhang D
PLoS One; 2013; 8(11):e78033. PubMed ID: 24223757
[TBL] [Abstract][Full Text] [Related]
18. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
19. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
20. d-Pinitol promotes tau dephosphorylation through a cyclin-dependent kinase 5 regulation mechanism: A new potential approach for tauopathies?
Medina-Vera D; Navarro JA; Rivera P; Rosell-Valle C; Gutiérrez-Adán A; Sanjuan C; López-Gambero AJ; Tovar R; Suárez J; Pavón FJ; Baixeras E; Decara J; Rodríguez de Fonseca F
Br J Pharmacol; 2022 Oct; 179(19):4655-4672. PubMed ID: 35760415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
